Somalogic Launches Validation Studies of Protein Biomarkers for Pancreatic Cancer and Mesothelioma

The validation trials will each involve on the order of 400 patients and should be completed within a year, said a company official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.